Noah Stansfield

SLN124 was well-tolerated in a previous clinical trial involving healthy volunteers.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Of 55 evaluable patients in ZUMA-3, 71% achieved complete remission (CR) or CR with incomplete hematological recovery (CRi).

Immusoft plans to begin the phase 1 clinical trial of ISP-001 before the end of 2022.

The study’s primary end points are change in visual acuity and the occurrence of adverse events.

The risk-benefit assessment determined that there are no significant safety concerns.

RGX-121 was well-tolerated across all 3 of the dose cohorts with no treatment-related serious adverse events reported.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A pre-treatment TME with high levels of cytokines and chemokines was associated with complete response to axi-cel treatment.

In an ovarian cancer mouse model, the combination therapy group showed an 83% increase in survival duration compared to an untreated group.

The study will be carried out in Paris and is expected to begin before the end of the year.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A case study showed that the patient achieved a complete response in 12 months after treatment with CARsgen Therapeutics’ cell therapy.

Thirty-five patients were previously treated with Innovative Cellular Therapeutics’ GCC19CART in an IRB-approved trial in China.

All patients with NMOSD who received CT103A showed improved Expanded Disability Status Scale scores.

The BLA was supported by data from 2 intrapatient, placebo-controlled clinical trials.

Higher doses were associated with improved overall survival, event-free survival, and relapse-free survival.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The novel therapy targets a hormone receptor only expressed at immunologically relevant levels in the ovaries.

Preclinical data showed a reduction of Gys1 mRNA and protein of more than 80% in multiple skeletal tissues.

Preclinical data showed hARSA activity levels in the brain that are predictive of functional improvements.

AstroRx previously demonstrated clinically meaningful reductions in the rate of disease progression.

Nula-cel is intended to directly correct the mutation that causes sickle cell disease.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

MyoAAV was shown to deliver 25 to 50 times greater gene expression in multiple skeletal muscles compared with natural AAV serotypes.

Among the programs involved are therapies for multiple myeloma and B-cell malignancies.

Pre-clinical data showed that EZ-T cells have increased anti-tumor activity compared with traditional iPSC-derived T-cells.

Topline results are expected to be announced by the fourth quarter of 2022.

Incidences of graft versus host disease will be a focal point of the study.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.